Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments December 13, 2022 READ MORE
Nimble Therapeutics included among the 2022 Best Places to Work by Madison Magazine September 15, 2022 READ MORE
Discovery of anti-Formin-like 1 protein (FMNL1) antibodies in membranous nephropathy and other glomerular diseases August 11, 2022 READ MORE
Nimble Therapeutics Announces Achievement of Development Milestones from Multiple Partnered Programs Connected to a Strategic Large Pharma Collaboration May 17, 2022 READ MORE
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody December 23, 2021 READ MORE
